 Sarepta Therapeutics, Inc. net product revenues for Q4 2022 are expected to come in about 32 higher at 235.5 million; Financial results for Q4 2022 are expected late February 2023. BLA of SRP-9001 for the treatment of patients with Duchenne Muscular Dystrophy was accepted November 2022, Priority Review date established for May 29, 2023. 